Novartis takes $485m hit after axing eczema drug from pipelineNovartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Share XNovartis takes $485m hit after axing eczema drug from pipelinehttps://pharmaphorum.com/news/novartis-takes-485m-hit-after-axing-eczema-drug-from-pipeline/
Plug and Play aims to accelerate Almirall’s digital start-upsAlmirall has announced a partnership with Plug and Play, a health tech accelerator and innovation platform, to boost Share XPlug and Play aims to accelerate Almirall’s digital start-upshttps://pharmaphorum.com/news/plug-and-play-aims-to-accelerate-almiralls-digital-start-ups/
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and Share XAlmirall strikes option deal to buy Bioniz and dermatology drug BNZ-1https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/
How big pharma and startups can learn from each otherFrancesca Wuttke’s varied career has taken her from research roles to private equity and now to the role Share XHow big pharma and startups can learn from each otherhttps://deep-dive.pharmaphorum.com/magazine/digital-health/almriall-startups-francesca-wuttke-digital/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
Almirall signs atopic dermatitis R&D deal with HitgenAlmirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for Share XAlmirall signs atopic dermatitis R&D deal with Hitgenhttps://pharmaphorum.com/news/almirall-signs-atopic-dermatitis-rd-deal-with-hitgen/
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasisNICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but Share XNICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasishttps://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
Almirall buys Allergan’s derma portfolioAlmirall is expanding its business by buying Allergan’s dermatology portfolio. The Spanish pharma company will buy five brands Share XAlmirall buys Allergan’s derma portfoliohttps://pharmaphorum.com/news/almirall-buys-allergans-derma-portfolio/
